Senores Pharmaceuticals’ shares debuted with over a 50% premium on Indian exchanges, reflecting a robust investor response to the IPO, which was subscribed over 93 times. The company focuses on pharmaceutical products for regulated markets and has strong revenue and profit growth in FY24.
